TARGET AUDIENCE
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of hematologic cancer.

OVERVIEW OF ACTIVITY
Currently more than 45 drug products are labeled for use in the management of hematologic cancer with more than 55 distinct FDA-approved indications. Although this extensive list of available treatment options is reassuring for patients and oncology professionals, it poses a challenge to the practicing clinician who must maintain up-to-date knowledge of appropriate clinical management strategies across a vast spectrum of tumor types.



Practicing oncologists and their patients regularly turn to clinical investigators at academic and tertiary care centers for advice, answers and second opinions as they attempt to make the often complex and difficult clinical decisions they are confronting. In this capacity and through their roles as trusted educators, counselors and adjudicators, these experts observe patterns, develop insights and gain experiences that in totality represent a treasure trove of information that remains largely untapped. This activity will assist in the development of up-to-date clinical management strategies for multiple myeloma (MM) and non-Hodgkin lymphoma (NHL) that will be useful to hematologists, medical oncologists and other healthcare providers in the clinic.

LEARNING OBJECTIVES

• Appraise recent data on therapeutic advances and changing practice standards in MM and NHL, including chronic lymphocytic leukemia (CLL), and integrate this information, where appropriate, into current clinical care.
• Use available research evidence to guide the selection of cytotoxic and/or biologic regimens for patients with newly diagnosed and relapsed/refractory CLL.
• Develop an algorithm for the risk-stratified induction treatment of patients with follicular lymphoma, diffuse large B-cell lymphoma and mantle-cell lymphoma.
• Recognize the role of novel agents in the management of peripheral T-cell lymphoma and/or advanced-stage cutaneous T-cell lymphoma, and ensure appropriate supportive care measures to minimize side effects.
• Compare and contrast the benefits and risks of immunomodulatory agents, proteasome inhibitors or both as systemic treatment for active MM.
• Identify patients with MM who may benefit from maintenance systemic treatment in both the post-transplant and nontransplant settings.
• Recall new data with investigational agents demonstrating promising activity in NHL and MM.
• Assess the ongoing clinical trials evaluating innovative investigational approaches for NHL and MM, and refer appropriate patients for study participation.

ACCREDITATION STATEMENT
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME credit is no longer available for this issue

CREDIT DESIGNATION STATEMENT

CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY
This CME activity consists of a video component. The participant should watch the video.

CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:

Nathan H Fowler, MD
Co-Director of Clinical and Translational Research
Lead, Phase I and Indolent Research Groups
Department of Lymphoma/Myeloma
The University of Texas MD Anderson Cancer Center
Houston, Texas

Advisory Committee: Celgene Corporation, Roche Laboratories Inc, Spectrum Pharmaceuticals Inc; Contracted Research: Celgene Corporation, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc.

Kenneth C Anderson, MD
Kraft Family Professor of Medicine
Harvard Medical School
Director, Jerome Lipper Multiple Myeloma Center
Director, LeBow Institute for Myeloma Therapeutics
Dana-Farber Cancer Institute
Boston, Massachusetts

Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Gilead Sciences Inc, Onyx Pharmaceuticals Inc, Sanofi; Other Remunerated Activities: Acetylon Pharmaceuticals Inc.

John P Leonard, MD
Richard T Silver Distinguished Professor of Hematology and Medical Oncology
Associate Dean for Clinical Research
Weill Cornell Medical College
New York, New York

Consulting Agreements: Biotest Pharmaceuticals Corporation, Celgene Corporation, Genentech BioOncology, Gilead Sciences Inc, GlaxoSmithKline, Hospira Inc, Johnson & Johnson Pharmaceuticals, MedImmune Inc, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc, Pharmacyclics Inc, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc, Teva Oncology.

Robert Z Orlowski, MD, PhD
Director, Myeloma Section
Professor of Medicine
Departments of Lymphoma/Myeloma and Experimental Therapeutics
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Advisory Committee: Abbott Laboratories, Array BioPharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Millennium: The Takeda Oncology Company; Contracted Research: Celgene Corporation, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc.

Owen A O’Connor, MD, PhD
Professor of Medicine and Developmental Therapeutics
Director, Center for Lymphoid Malignancies
Columbia University Medical Center
College of Physicians and Surgeons
NewYork-Presbyterian Hospital
New York, New York

Advisory Committee: Allos Therapeutics, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Onyx Pharmaceuticals Inc, Spectrum Pharmaceuticals Inc; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Millennium: The Takeda Oncology Company.

Sonali M Smith, MD
Associate Professor
Section of Hematology/Oncology
Director, Lymphoma Program
The University of Chicago
Chicago, Illinois

Advisory Committee: Allos Therapeutics, Amgen Inc, Celgene Corporation, Genentech BioOncology, Onyx Pharmaceuticals Inc, Seattle Genetics.

MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from Celgene Corporation, Genentech BioOncology/Biogen Idec, Millennium: The Takeda Oncology Company, Onyx Pharmaceuticals Inc and Teva Oncology.

Hardware/Software Requirements:
A high-speed Internet connection  
A monitor set to 1280 x 1024 pixels or more
Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
Adobe Flash Player 10.2 plug-in or later
Adobe Acrobat Reader
(Optional) Sound card and speakers for audio

Last review date: August 2013
Expiration date: August 2014